COVID-19: WHO study points to ‘conclusive evidence’ of inefficiency of hydroxychloroquine – Health


(Photo: STR / AFP)

The World Health Organization (WHO) presented, on Thursday (15), what it called “evidence conclusive” gives inefficiency gives hidroxicloroquina and three more antivirals in the COVID-19 combat: remdesivir, hydroxychloroquine, lopinavir / ritonavir (combination) and interferon beta-1a.

The analysis appears in the pre-publication The “Solidarity Therapeutics Trial”, led by the World Health Organization (WHO) in 405 hospitals, in more than 30 countries. The search awaits the approval of scientific journals and review by other specialists.

The study involved 11,266 people. Of that total, 2,750 took remdesivir; 954 took hydroxychloroquine; 1,411 took lopinavir; 651, interferon and lopinavir; 1,412 took only interferon; and 4,088 were part of the control group, which was not medicated.

One thousand two hundred and fifty-three patients died. THE concluded of the scientists was that the drugs were not able to reduce mortality from the new coronavirus, nor did they decrease the length of hospital stay or recovery of patients who survived.

The randomized clinical trial is considered the gold standard in evidence-based medicine. According to the WHO, although the study needs to be screened by other specialists, the evidence produced on the drugs in question is “conclusive”.

“The progress made by the ‘Solidarity Therapeutics Trial’ shows that large international trials are possible even during a pandemic, and offer the promise of answering critical public health issues regarding treatment quickly and reliably,” says the text published by organize.


Please enter your comment!
Please enter your name here